College of Transdisciplinary Sciences for Innovation, Kanazawa University, Kanazawa, Japan.
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
BMJ Open. 2022 Dec 20;12(12):e063489. doi: 10.1136/bmjopen-2022-063489.
Japan is one of the largest markets for heated tobacco products (HTPs), and the number of HTP users, including dual users, is growing. However, it is not yet clear whether a telemedicine smoking cessation programme is effective for nicotine-dependent HTP users to quit smoking. We assessed the outcomes of a telemedicine smoking cessation programme in terms of continuous smoking cessation among smokers who had used HTPs compared with those who used exclusively cigarettes.
A retrospective cohort study to assess the outcomes of the telemedicine smoking cessation programme provided by Linkage, Japan, comparing the success rates of smoking cessation between exclusively cigarette group (as reference) and HTP user groups (exclusively HTPs or dual use of both cigarettes and HTPs).
Linkage telemedicine smoking cessation programme database, covering programme participants in Japan.
Programme participants from between August 2018 and October 2020.
Continuous abstinence rates (CARs) from 9 to 24 weeks (CAR9-24) and 9 to 52 weeks (CAR9-52). Adjusted ORs (aORs) with 95% CIs for CAR were calculated to compare the exclusively cigarette group with exclusively HTP and dual use groups.
We analysed 733 telemedicine smoking cessation programme participants. Exclusively HTP users had higher CARs than the exclusively cigarette group for CAR9-24 (aOR 1.12, 95% CI 1.02 to 1.23; p=0.02) and CAR9-52 (1.09, 0.99 to 1.19; p=0.08). Conversely, dual users had lower CARs than the exclusively cigarette group for CAR9-24 (0.85, 0.76 to 0.95; p=0.004) and CAR9-52 (0.88, 0.79 to 0.97; p=0.01).
Exclusive HTP users achieved higher CARs, whereas dual users had lower CARs than exclusively cigarette users over short-term and long-term periods. A telemedicine smoking cessation programme may be a reasonable option for exclusive HTP users.
日本是加热烟草制品（HTP）的最大市场之一，包括双重使用者在内的 HTP 用户数量正在增长。然而，尚不清楚远程医疗戒烟计划对于依赖尼古丁的 HTP 用户戒烟是否有效。我们评估了远程医疗戒烟计划在 HTP 使用者与仅使用香烟者的连续戒烟方面的结果。
一项回顾性队列研究，评估了由日本 Linkage 提供的远程医疗戒烟计划的结果，比较了仅使用香烟组（作为参考）和 HTP 用户组（仅使用 HTP 或同时使用香烟和 HTP）的戒烟成功率。
Linkage 远程医疗戒烟计划数据库，涵盖日本计划参与者。
2018 年 8 月至 2020 年 10 月期间的计划参与者。
9 至 24 周（CAR9-24）和 9 至 52 周（CAR9-52）的持续戒烟率（CAR）。计算调整后的比值比（aOR）及其 95%置信区间（CI），以比较仅使用香烟组与仅使用 HTP 组和双重使用组。
我们分析了 733 名远程医疗戒烟计划参与者。与仅使用香烟组相比，仅使用 HTP 使用者在 CAR9-24（aOR 1.12，95%CI 1.02 至 1.23；p=0.02）和 CAR9-52（1.09，0.99 至 1.19；p=0.08）时的 CAR 更高。相反，与仅使用香烟组相比，双重使用者在 CAR9-24（0.85，0.76 至 0.95；p=0.004）和 CAR9-52（0.88，0.79 至 0.97；p=0.01）时的 CAR 更低。
与仅使用香烟者相比，仅使用 HTP 使用者在短期和长期内获得了更高的 CAR，而双重使用者的 CAR 则较低。远程医疗戒烟计划可能是 HTP 使用者的合理选择。
